Judge Grants Final Approval to Bayer's $7.25 Billion Roundup Class Settlement Covering Future Cancer Claims
A St. Louis judge overruled objections to the deal, which pays Roundup lymphoma claims for up to 21 years, though any appeal will pause payments.
A St. Louis judge on Friday, November 20, 2026, granted final approval to Bayer's nationwide class settlement of Roundup cancer claims, a deal worth up to $7.25 billion that is designed to resolve both pending lawsuits and claims from people who have not yet been diagnosed. Circuit Judge Timothy Boyer found the agreement "fair, reasonable, and adequate" and overruled objections that individual payouts would be too low compared with what earlier settling plaintiffs received.
The ruling gives Bayer and its Monsanto unit a path to close out most of the litigation that has followed the company since it bought Monsanto for $63 billion in 2018. Bayer said in a statement that the order can be appealed and that any appeal would pause Monsanto's payments until all appeals are exhausted.
What the settlement covers
The class includes people who allege exposure to Roundup before February 17, 2026, and who either already have a non-Hodgkin lymphoma diagnosis or receive one within 16 years after the agreement takes effect, according to Bayer. It covers claims regardless of the legal theory behind them, and it contains no admission of liability or wrongdoing.
Monsanto will fund a long-term claims program through declining, capped annual payments for up to 21 years, with total payments of up to $7.25 billion, including amounts already paid. St. Louis Public Radio reported that individual awards are expected to range from $10,000 to $165,000, that a separate $1 billion fund protects against funding shortfalls, and that more than $400 million is set aside for claimants with special circumstances. According to AgWeb, awards depend on how a person was exposed, their age at diagnosis and the type of lymphoma.
Reuters reported that Bayer faced about 65,000 pending claims in state and federal courts and that the deal excludes some lawsuits pending in federal court, about 200 of which Bayer says are still being litigated. Bayer has said it expects opt-outs to be a very low percentage of current and potential future claims, but it did not give a figure.
The Supreme Court ruling behind the deal
The approval follows the U.S. Supreme Court's June 25, 2026, decision in Monsanto v. Durnell, which held 7-2 that the federal pesticide law, FIFRA, preempts state failure-to-warn claims that would require a cancer warning the Environmental Protection Agency has not required. The ruling overturned a $1.25 million jury award to John Durnell, a Missouri man who blamed glyphosate exposure for his lymphoma.
On October 29, 2026, in Aretino v. Monsanto, the first Roundup trial since the ruling, a St. Louis County jury returned a unanimous defense verdict after the court found the warning claims preempted and the plaintiffs lost on design defect, fraud and negligence theories. Bill Dodero, Bayer's U.S. general counsel and global litigation leader, has said the verdict signals future plaintiffs will face significant challenges.
Christopher Seeger of Seeger Weiss, a lawyer for many of the claimants, said the Durnell decision narrowed victims' ability to sue and that he wants to get relief to them as quickly as possible. Judge Boyer noted that delays could leave victims, including those with terminal cancer, waiting an indeterminate number of years for payment.
Bayer CEO Bill Anderson called the approval "a decisive milestone in the company's strategy" to manage the risk of pending and future Roundup cases. Bayer continues to deny that Roundup or its active ingredient, glyphosate, causes cancer. The company settled much of the litigation in 2020 for $10.9 billion, but a separate $1.25 billion plan for future claims failed to win court approval, leaving the future-claimant problem open until this deal.
What this means for in-house counsel
The Bayer structure shows a way to bind people who are not yet sick: a state-court class with a fixed exposure cutoff date, a 16-year diagnosis window, declining, capped annual payments for up to 21 years and a reserve fund against shortfalls. Legal teams managing long-tail product exposure should note that the payment obligation stays suspended while appeals run, so reserve and disclosure planning should account for both the timing of any appeal and the risk that objectors keep the order from becoming final.
For pesticide makers and other companies whose labels must be approved by the EPA under FIFRA, Durnell raises the value of documenting exactly what the agency reviewed and approved. The Court held that FIFRA's preemption clause bars state failure-to-warn claims seeking a cancer warning the EPA did not require on an approved label. Product and regulatory counsel should preserve registration records, label approvals and EPA correspondence, and note that the ruling does not reach design defect, fraud or negligence claims. Whether the reasoning extends to other federal labeling regimes remains an open argument.
Free weekly email
The Counsel House Brief
The week's most important legal news for general counsel and in-house teams, in one short email.
Counsel House corrects errors promptly. Spot one? Email daniel@counselhouse.org.